Berotralstat

Brand names: Orladeyo · Active ingredient: Berotralstat Hydrochloride

In short: ORLADEYO® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older. Limitations of Use: The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established.

Forms & strengthsCapsules: 150 mg: a white opaque body with a black imprint "150" and a light blue opaque cap with a black imprint "BCX". 110 mg: light blue opaque body and cap with a white imprint "110" on body and a white imprint "BCX" on cap. …
LabelBioCryst Pharmaceuticals Inc.
Label updatedOct 28, 2026

What is Berotralstat used for?

ORLADEYO® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older.

Limitations of Use:

The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for treatment of acute HAE attacks. Additional doses or doses of ORLADEYO higher than the prescribed once-daily dose are not recommended due to the potential for QTc interval prolongation .

Berotralstat dosage

The recommended dosage of ORLADEYO for adults and pediatric patients 12 years of age and older is 150 mg taken orally once daily with food .

The recommended dosage of ORLADEYO oral pellets for pediatric patients 2 years to less than 12 years of age is based on the patient's body weight as provided in Table 1. Take ORLADEYO orally with food .

Body Weight (kg) | Recommended Dosage of ORLADEYO Oral Pellets

12 kg to less than 24 kg | 72 mg once daily

24 kg to less than 32 kg | 96 mg once daily

32 kg to less than 40 kg | 108 mg once daily

40 kg or greater | 132 mg once daily

Mild Hepatic Impairment (Child-Pugh Class A)

Adult and Pediatric Patients 2 Years of Age and Older

No dosage modification of ORLADEYO is recommended .

Moderate or Severe Hepatic Impairment (Child-Pugh Class B or C)

Adult and Pediatric Patients 12 Years of Age and Older

Recommended dosage of ORLADEYO capsules is 110 mg taken orally once daily with food .

Pediatric Patients 2 Years to Less than 12 Years of Age

Avoid use of ORLADEYO .

Gastrointestinal (GI) reactions may occur in patients receiving ORLADEYO .

For adults and pediatric patients 12 years of age and older, if GI adverse reactions persist, consider a lower ORLADEYO capsules dosage of 110 mg once daily with food.

For pediatric patients 2 to less than 12 years of age with persistent GI adverse reactions, consider the risks and benefits of continuing treatment with ORLADEYO.

Do not chew or crush ORLADEYO oral pellets because this will affect the film coating (taste masking) and result in bitter taste. A meal should be consumed just before or after dosing. Administer one packet of oral pellets as follows:

Pour the entire contents of one packet directly into the mouth and swallow immediately with non-acidic liquid (e.g., water or milk). OR

Sprinkle the entire contents of one packet over approximately one tablespoon (15 mL) of soft, non-acidic food and consume immediately. Food should be at or below room temperature. Examples of soft, non-acidic foods include pudding, mashed potatoes, creamed corn, pureed peas, pureed bananas, and pureed carrots. Acidic foods such as yogurt and applesauce should not be used because they can dissolve the film coating (taste masking) and result in a bitter taste. The film coating (taste masking) remains intact for 10 minutes. If the pellets are not consumed within 10 minutes of sprinkling over food, they should be discarded.

How to take Berotralstat — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Inform patients of the risks and benefits of ORLADEYO before prescribing or administering to the patient.

Not for Acute Treatment of HAE Attacks

Advise patients to take their usual rescue medication to treat an acute attack of HAE. Inform patients that the safety and effectiveness of ORLADEYO has not been established as a treatment for acute HAE attacks .

QTc Prolongation with Higher Than Recommended Dosages

Advise patients that they should not take daily doses higher than their prescribed once-daily dose or additional doses of ORLADEYO to treat an acute attack of HAE due to risk of QTc interval prolongation .

Administration Instructions for Oral Pellets

Instruct patients that ORLADEYO oral pellets should not be chewed or crushed because this will affect the film coating, which masks the bitter taste. Advise patients to take ORLADEYO oral pellets by pouring one packet directly into the mouth and swallowing with a non-acidic liquid (e.g., water or milk), or to sprinkle one packet over one tablespoon of soft, non-acidic food and consume immediately . …

Warnings & precautions

Do not take this medicine if: None.

ORLADEYO should not be used for treatment of acute attacks of HAE. Additional doses or doses of ORLADEYO higher than the recommended dosage are not recommended. An increase in QTc interval was observed in adults at dosages higher than 150 mg once daily and was concentration dependent .

Berotralstat side effects

The following clinically significant adverse reaction is described elsewhere in the labeling:

QTc Interval Prolongation .

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions in Adult and Pediatric Patients 12 Years of Age and Older

The safety of ORLADEYO is primarily based on 24-week (Part 1) data from a 3-part, double-blind, parallel-group, placebo-controlled trial (Trial 1) in 120 patients with Type I or II HAE who were randomized and dosed with either ORLADEYO 110 mg, 150 mg, or placebo, once daily with food. After Week 24, patients who continued in the study received active treatment through 48 weeks.

In Trial 1, a total of 81 patients aged 12 years and older with HAE received at least one dose of ORLADEYO in Part 1. Overall, 66% of patients were female and 93% of patients were White with a mean age of 41.6 years. The proportion of patients who discontinued study drug prematurely due to adverse reactions was 7% and 3% for patients treated with ORLADEYO 110 mg and 150 mg, respectively, and 3% for placebo-treated patients. No deaths occurred in the trial.

The safety profile of ORLADEYO was generally similar across all subgroups of patients, including analysis by age, sex, and geographic region. …

Drug interactions

P-gp Inducers

Berotralstat is a substrate of P-gp and BCRP. P-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. Avoid concomitant use of P-gp inducers with ORLADEYO.

CYP2D6 and CYP3A4 Substrates

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. Concomitant use of ORLADEYO with CYP2D6 or CYP3A4 substrates can increase exposure of the CYP2D6 or CYP3A4 substrates and may increase the risk of adverse reactions associated with the substrates. If ORLADEYO is concomitantly used with CYP2D6 or CYP3A4 substrates where minimal increases in the concentration of the substrates may lead to serious adverse reactions, closely monitor or modify the dosage of the CYP2D6 or CYP3A4 substrate . Refer to the Prescribing Information of the CYP2D6 or CYP3A4 substrate.

Desogestrel

Concomitant use of ORLADEYO with desogestrel increases exposure to etonogestrel, the active metabolite of desogestrel, and may increase the risk of desogestrel-associated adverse reactions. Consider the benefits and risks when using ORLADEYO concomitantly with desogestrel . …

About this medicine

ORLADEYO (berotralstat) is a plasma kallikrein inhibitor. Berotralstat is presented as the dihydrochloride salt with the chemical name 1-[3-(aminomethyl)phenyl]-N-(5-{(R)-(3-cyanophenyl)[(cyclopropylmethyl)amino]methyl}-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride. The chemical structure is:

Berotralstat dihydrochloride is a white to off-white powder that is soluble in water at pH ≤4. The molecular formula is C30H26F4N6O ∙ 2HCl and the molecular weight is 635.49 (dihydrochloride).

ORLADEYO (berotralstat) capsules contain 150 mg of berotralstat (equivalent to 169.4 mg berotralstat dihydrochloride) or 110 mg of berotralstat (equivalent to 124.3 mg berotralstat dihydrochloride) in hard gelatin capsules for oral administration. Each capsule contains the active ingredient berotralstat dihydrochloride and the inactive ingredients colloidal silicon dioxide, crospovidone, magnesium stearate, and pregelatinized starch. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3527ece1-e7e0-40b1-b0c5-6baeb0deabeb. Read the full official label on DailyMed.